<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="./css/bootstrap.min.css">
    <link rel="stylesheet" href="./css/all.min.css">
    <link rel="stylesheet" href="./css/fontawesome.min.css">
    <link rel="stylesheet" href="./css/style.css">
    <title>Diabetes 360 eMagazine</title>
</head>
<body>


    <div class="container">
    <div class="main">
        <div class="left">
            <a href="./page-7.html"><img src="./img/prev.png" alt="previous"></a>
        </div>
        <div class="right">
            <a href="./page-9.html"><img src="./img/next.png" alt="next"></a>
        </div>
        
        <header class="pages-header-footer pages-h-f-white">
            <div class="row align-items-center m-0">
                <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                <div class="col-7 align-content-center"><div class="dark-line"></div></div>
                <div class="col-2"><img src="img/sanofi-logo-black.png" alt=""></div>
            </div>
        </header>
        <div class="article-head">
            <h1 class="headline">
                <span class="bold">
                    Comparative Efficacy and Safety of Gla 300 versus
IDegAsp in Insulin-naïve People with Type 2 Diabetes
Mellitus Uncontrolled on Oral Anti-diabetics
            </span> </h1>
                <hr>
                <div class="subheader">
                    <p class="primary-col">
                        Source: Ritzel R, Ghosh S, Emral R, Malek R, Zeng L, Mabunay MA, Landgraf W, Guyot P, Serafini P, Pushkarna D, Malik RA. Comparative
efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15121.
                    </p>
                </div>
        </div>
        <article>
            <div class="row">
                <div class="col-lg-6 col-sm-12">
                    <div class="feature-img">
                        <img src="./img/magazine-edit-13-3-19.jpg" alt="feature-img">
                    </div>
                    <p>
                        Insulin glargine injection is a long-acting secondgeneration
                        basal insulin containing 300 units/ml of
                        insulin glargine (Gla-300). Randomized controlled trial
                        (RCT) evidence showed an improved pharmacokinetic
                        and pharmacodynamic profile of Gla-300 compared with
                        Gla-100, with a lower risk of hypoglycemia and slightly
                        less weight gain. Insulin degludec and insulin aspart
                        (IDegAsp) injection 70/30 is a premixed combination of
                        a long-acting second-generation basal insulin analogue
                        and a rapid-acting human insulin analogue. RCT
                        evidence comparing IDegAsp once daily with Gla-100
                        found a similar reduction in HbA<sub>1c</sub> and fasting plasma
                        glucose (FPG), but confirmed anytime hypoglycemia
                        was higher with IDegAsp once daily while confirmed
                        nocturnal hypoglycemia was higher with Gla-100.
                    </p>
                        <p>
                            Ritzel et al., aimed to compare the efficacy and safety
of Gla-300 with insulin IDegAsp once daily in patients
with type 2 diabetes (T2D) inadequately controlled on
oral anti-diabetic drugs (OADs).
                        </p>
                        <p>
                            A systematic literature review of randomized controlled
                            trials was followed by an indirect treatment comparison
                            5 of studies involving insulin naïve adults, inadequately
                            controlled [glycated hemoglobin (HbA<sub>1c</sub>) ≥7.0%] on
                            OADs, who received Gla-300 or IDegAsp once daily. The
                            outcomes of interest included change in HbA<sub>1c</sub>, blood
                        </p>

    
                </div>
    
                <div class="col-lg-6 col-sm-12">
                    <p>
                        glucose, weight and insulin dose, as well as incidence
and event rate of hypoglycemia and other adverse
events.
                    </p>
                    <p>
                        Four trials with broadly similar baseline patient
characteristics were included in the meta-analyses
and indirect treatment comparison. At 24-28 weeks,
the indirect comparison of Gla-300 to IDegAsp once
daily estimated no statistically significant difference for
change in HbA<sub>1c</sub> (%) from baseline [mean difference of
0.10% (95% CI: -0.20, 0.39; p=.52)]; a statistically significant
mean difference of -1.31 kg (95% CI: -1.97, -0.65; p&lt;.05)
for change in body weight from baseline; statistically
significant odds ratios of 0.62 (95% CI: 0.41, 0.93; p&lt;.05)
for incidence of any hypoglycemia; and 0.47 (95% CI:
0.25, 0.87; p&lt;.05) for incidence of anytime confirmed
hypoglycemia (plasma glucose &lt;3.0-3.1 mmol/L). No
significant differences were observed for insulin dose
and adverse events.
                    </p>
                    <p>
                        RWE obtained from analysis of more representative RWD
                    is becoming more and more relevant and significant for
                    a chronic nontransmissible disease such as diabetes,
                    and its application has grown over the past few years. It
                    is frequently used to supplement RCT results in clinical
                    effectiveness research, with the main benefits being low
                    cost and higher external validity.
                    </p>
                    <div class="purple-quote primary-bg">
                        <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                        <h3>Conclusion</h3>
                        <p>
                            This ITC shows no significant difference in
change in HbA<sub>1c</sub> and insulin dose at 24- 28 weeks
between Gla-300 and IDegAsp once daily.
However, Gla-300 was associated with less
weight gain and a lower risk of clinically
significant confirmed (PG &lt;3.0-3.1 mmol/L)
hypoglycemia and any hypoglycemia compared
with IDegAsp once daily.
There were differences in SMPG levels between
the two treatments. These findings suggest that
insulin- naïve patients with T2D inadequately
controlled on OADs commencing Gla-300
would probably experience less weight gain
and have a lower risk of clinically significant
hypoglycemia (PG &lt;3.0-3.1 mmol/L) compared
with commencing IDegAsp.
                        </p>
                    </div>
                    
                </div>
            </div>
            
            <div class="article-footer">
                <div class="row">
                    <div class="col-lg-6 col-sm-12">
                        <div class="ref-rating">
                            <p>
                                RCT, randomized controlled trial; ITC, indirect treatment comparison;
PG, plasma glucose; SMPG, self-monitored plasma glucose; T2D, type 2
diabetes; OADs, oral antidiabetic drugs
                            </p>                    
                        </div>
                        <div class="rating">
                            <p>How do you rate this article?</p>
                            <div class="row px-4">
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                            </div>
                            <div class="rating-bar">
                                <img src="./img/rating-1-5.png" alt="">
                            </div>  
                        </div>
                    </div>
                </div>
            </div>
        </article>
        </div>
        <footer class="footer">
            <div class="pages-header-footer">
                <div class="row">
                    <div class="col-1">
                        <div class="pagination">
                            <p>8</p>
                        </div>
                    </div>
                    <div class="col-8 align-content-center p-0">
                        <div class="dark-line"></div>
                    </div>
                    <div class="col-3 d-flex justify-content-center align-items-center">
                        <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                    </div>
                </div>
            </div>
        
    </footer>

        </div>

    </div>    
    </div>


    <script src="./js/bootstrap.bundle.min.js"></script>
    </body>
</html>